ELECTRONIC MOOD

Brand Owner Address Description
E-MOOD DURAVIT AG Werderstrasse 36 78132 Hornberg Germany ELECTRONIC-MOOD;Lamps, lights, lighting fixture and lighting apparatus;Glass holders, soap holders, toilet paper holders, toilet brushes and holders for toilet brushes; towel holders, not of precious metal; goods made of wood or wood substitutes, namely holders for soap, glasses, toilet paper and towels; paper towel dispensers made of metal (not-fixed); soap dispensers; all aforementioned goods for bathrooms and washrooms;Furniture, especially with integrated soap and/or towel dispensers, mirrors and/or consumer electronics appliances and/or connections therefor; mirrors, mirror cabinets, goods made of wood or wood substitutes, namely curtain rails, wall hooks, works of art, as far as included in this class; decorative objects, as far as included in this class; goods made of plastic, namely fittings for furniture, for windows and for doors; fittings not of metal for furniture and sanitary installations, wall hooks not of metal; storage trays for washbasins and washstands; towel dispensers (fixed), not of metal; all aforementioned goods for bathrooms and washrooms;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas.